在阿尔茨海默病中准过渡金属 (铜,铁和) 的最新进展
Raghuraj Singh1,2, Archna Panghal3, Krishna Jadhav2
1Pharmaceutical Nanotechnology Lab, Institutes of Nano Science and Technology (INST), Sector 81. Mohali, Punjab, 140306, India.
Molecular neurobiology
|May 29, 2024
概括
阿尔茨海默病 (AD) 涉及大脑金属平衡的改变,过多的铁,铜和可能导致氧化应激. 金属合疗法在治疗与这种金属dyshomeostasis相关的神经退行方面表现有前途.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默氏症 (AD) 与大脑中过渡金属平衡中断有关.
- 具体的变化包括在粉样斑块周围增加的神经元内铁和细胞外铜和的积累.
研究的目的:
- 审查过渡金属dyshomeostasis在阿尔茨海默氏病的发病过程中的作用.
- 探索结合疗法作为AD相关神经退行症治疗策略的潜力.
主要方法:
- 关于AD中金属恒温的研究的文献综述.
- 分析金属蛋白相互作用和神经退行症之间的联系.
- 检查治疗策略,特别是金属化药物.
主要成果:
- 铜,和铁的异常水平是AD大脑的特征.
- 由于金属不平衡而产生的氧化应激是阿尔茨海默病的一个被提议的致病因素.
- 金属蛋白相互作用对于神经退行发育或预防至关重要.
结论:
- 过渡金属双体平衡是阿尔茨海默病的一个重要因素.
- 化疗法代表了AD和金属诱导的神经退行症的潜在治疗途径.
更多相关视频
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...


